Developmental Programming in Response to Intrauterine Growth Restriction Impairs Myoblast Function and Skeletal Muscle Metabolism by Yates, Dustin T et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Faculty Papers and Publications in Animal Science Animal Science Department
5-25-2012
Developmental Programming in Response to
Intrauterine Growth Restriction Impairs Myoblast
Function and Skeletal Muscle Metabolism
Dustin T. Yates
University of Nebraska Lincoln & University of Arizona, dustin.yates@unl.edu
A.R. Macko
University of Arizona
M. Nearing
University of Arizona
X. Chen
University of Arizona
R.P. Rhoads
University of Arizona, vanrhoad@email.arizona.edu
See next page for additional authors
Follow this and additional works at: https://digitalcommons.unl.edu/animalscifacpub
Part of the Genetics and Genomics Commons, and the Meat Science Commons
This Article is brought to you for free and open access by the Animal Science Department at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Faculty Papers and Publications in Animal Science by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.
Yates, Dustin T.; Macko, A.R.; Nearing, M.; Chen, X.; Rhoads, R.P.; and Limesand, Sean W., "Developmental Programming in
Response to Intrauterine Growth Restriction Impairs Myoblast Function and Skeletal Muscle Metabolism" (2012). Faculty Papers and
Publications in Animal Science. 1045.
https://digitalcommons.unl.edu/animalscifacpub/1045
Authors
Dustin T. Yates, A.R. Macko, M. Nearing, X. Chen, R.P. Rhoads, and Sean W. Limesand
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/animalscifacpub/
1045
Hindawi Publishing Corporation
Journal of Pregnancy
Volume 2012, Article ID 631038, 10 pages
doi:10.1155/2012/631038
Review Article
Developmental Programming in Response to Intrauterine
Growth Restriction Impairs Myoblast Function and Skeletal
Muscle Metabolism
D. T. Yates,1 A. R. Macko,1 M. Nearing,1 X. Chen,1 R. P. Rhoads,2 and S. W. Limesand1, 3
1 Department of Animal Sciences, The University of Arizona, Tucson, AZ 85721-0038, USA
2 Department of Animal and Poultry Sciences, Virginia Tech, Blacksburg, VA 24061, USA
3 Agricultural Research Complex, Department of Animal Sciences, The University of Arizona, 1650 E. Limberlost Dr.,
Tucson, AZ 85719, USA
Correspondence should be addressed to S. W. Limesand, limesand@ag.arizona.edu
Received 1 April 2012; Accepted 25 May 2012
Academic Editor: Timothy Regnault
Copyright © 2012 D. T. Yates et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fetal adaptations to placental insufficiency alter postnatal metabolic homeostasis in skeletal muscle by reducing glucose oxidation
rates, impairing insulin action, and lowering the proportion of oxidative fibers. In animal models of intrauterine growth restriction
(IUGR), skeletal muscle fibers have less myonuclei at birth. This means that myoblasts, the sole source for myonuclei accumulation
in fibers, are compromised. Fetal hypoglycemia and hypoxemia are complications that result from placental insufficiency.
Hypoxemia elevates circulating catecholamines, and chronic hypercatecholaminemia has been shown to reduce fetal muscle
development and growth. We have found evidence for adaptations in adrenergic receptor expression profiles in myoblasts and
skeletal muscle of IUGR sheep fetuses with placental insufficiency. The relationship of β-adrenergic receptors shifts in IUGR
fetuses because Adrβ2 expression levels decline and Adrβ1 expression levels are unaffected inmyofibers and increased inmyoblasts.
This adaptive response would suppress insulin signaling, myoblast incorporation, fiber hypertrophy, and glucose oxidation.
Furthermore, this β-adrenergic receptor expression profile persists for at least the first month in IUGR lambs and lowers their
fatty acid mobilization. Developmental programming of skeletal muscle adrenergic receptors partially explains metabolic and
endocrine differences in IUGR offspring, and the impact on metabolism may result in differential nutrient utilization.
1. Introduction
Intrauterine growth restriction (IUGR) affects 10–15% of all
infants born in the USA and asmany as 24% of babies born in
developing countries [1, 2]. Worldwide, IUGR is the second
leading cause of perinatal morbidity and mortality behind
premature birth [3] and is a major predisposing factor to
metabolic disorders throughout postnatal life [4, 5]. Chil-
dren born SGA due to IUGR are more likely to develop
insulin resistance and obesity at young ages [6–8]. As adults,
these individuals face greater incidence of type 2 diabetes,
hypertension, and other health issues [9–12]. In fact, IUGR
offspring are 18 times more likely to develop metabolic syn-
drome than offspring born at an appropriate size for their
gestational age (AGA) [10, 13]. Preterm infants may also be
predisposed to metabolic disorders later in life. Though AGA
at birth, these infants are often growth-restricted between
birth and term because their oral intake of protein cannot
match the levels supplied by the placenta [14]. Skeletal mus-
cle accounts for ∼40% of the body’s mass and thus plays a
major role in metabolic homeostasis. Growth and metab-
olism of skeletal muscle are influenced by a number of fac-
tors, including nutrient availability, growth factors, and
endocrine signals. In this paper, we will focus on the role
of the adrenergic system in fetal adaptations to intrauterine
insults alter growth, development, and metabolic set-points
in skeletal muscle during late gestation and throughout
postnatal life.
2. IUGR Conditions: Hypoxemia,
Hypoglycemia, and Hypercatecholaminemia
A frequent cause of IUGR is placental insufficiency [15],
which can occur spontaneously and from undiagnosed
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etiology. As the fetus grows, the stunted placenta cannot
keep up with the increasing nutritional demands of the
fetus, resulting in chronic fetal hypoglycemia and hypox-
emia throughout late gestation. These conditions elevate
circulating catecholamine concentrations [16]. Plasma nore-
pinephrine and epinephrine concentrations are modestly
elevated by fetal hypoglycemia [17–19] but greatly elevated
by hypoxemia [20, 21]. Fetal adrenal chromaffin cells contain
oxygen-sensitive K+ channels that stimulate catecholamine
secretion in response to low blood oxygen content, while the
splanchnic nerve develops [21, 22]. In IUGR human and rat
fetuses, hypoxemia increases catecholamine concentrations
in plasma and amniotic fluid by as much as 5-fold [23–25].
Plasma epinephrine and norepinephrine are also elevated in
IUGR fetal sheep where placental insufficiency is the known
etiology [26–28]. Catecholamines act via the G-protein
coupled receptors, Adrα and Adrβ [29, 30], which express
multiple subtypes (α1A, α1B, α1D, α2A, α2B, α2C, β1, β2,
and β3) with distinct physiological and pharmacological
properties [31]. Receptor expression patterns determine
how tissues respond to catecholamines, and skeletal muscle
predominantly expresses Adrβ1 and Adrβ2 subtypes, but
Adrβ3 and Adrα subtypes are also present. Even in healthy
pregnancies, brief cord occlusions and Poseiro effects cause
transient periods of fetal hypoxemia and hypoglycemia [32,
33], making it necessary for the fetus to have a protective
mechanism to conserve glucose and oxygen. Skeletal muscle
accounts for ∼65% of fetal glucose consumption and its
metabolic functions are responsive to endocrine regulation
[34], making it a prime site for glucose and oxygen conserva-
tion.
3. Fetal Adaptive Response to IUGR Conditions
Both hypoxemia and hypoglycemia can impact global fetal
metabolism, and the response depends upon the duration
of the insult. We have shown that acute (<1 hour) fetal
hypoxemia suppresses glucose-stimulated insulin secretion
by increasing circulating norepinephrine and epinephrine
(Yates and Limesand, unpublished), which then activate
inhibitory Adrα2 receptors on pancreatic β-cells [20, 26, 35,
36]. The combination of high circulating catecholamines and
low insulin concentrations contributes to hyperlactatemia,
acidosis, and hypocarbia in the fetus [37] (Yates and
Limesand, unpublished). We postulate that this reflects a
temporary reduction in skeletal muscle glucose oxidation to
spare glucose and oxygen for neural tissues. This transient
coping mechanism is accompanied by increased utilization
of nonglucose substrates for energy production. To illustrate,
skeletal muscle enzymes associated with fatty acid oxidation
are upregulated in fetal rats 24 hours after uterine artery liga-
tion [38], and fatty acid mobilization rates in the sheep fetus
increase after six hours of hypoglycemia [17]. Additionally,
a greater proportion of amino acids are diverted for oxi-
dization in these fetal sheep [39, 40]. Placental insufficiency
causes a chronic state of fetal hypoxemia and hypoglycemia,
and therefore hypercatecholaminemia and suppression of
glucose oxidation are sustained. As a result, endocrine and
metabolic adaptations develop to conserve fetal nutrients
by lowering skeletal muscle energy requirements for protein
synthesis and growth [41–43]. Accordingly, amino acid oxi-
dation rates in the fetal sheep return to normal after the 8th
week of hypoglycemia [41]. Similarly, the ability to mobilize
fatty acids is reduced in the IUGR sheep fetus near term [44–
46]. In addition to lower oxidative metabolism, the IUGR
fetus induces hepatic glucose production and the Cori cycle
[47], which utilizes lactate produced by anaerobic glycolysis
in skeletal muscle as a substrate for glucose [47, 48]. Lactate
clearance by the liver stabilizes plasma lactate concentrations
in IUGR fetuses, creating only mild hyperlactatemia [47]
compared to acutely hypoxemic fetuses. Thus, long durations
of nutrient or oxygen deprivation produce a metabolic shift
that may be explained by adaptations to catecholamine levels
in fetal circulation.
Comparisons between fetal sheep made chronically hyp-
oglycemic and those with placental insufficiency (hypoxemic
and hypoglycemic) show that hypoxemia has a greater
propensity than hypoglycemia for inducing metabolic adap-
tations, possibly due to greater adrenergic activity associated
with hypoxemia. Chronic hypoglycemia increases protein
breakdown and rates of amino acid oxidation, lowers plasma
insulin and glucose uptake, and slows fetal growth rate,
but the response is transient and euglycemic recovery
normalizes these parameters within a few days [39, 49].
Conversely, in fetal sheep with placental insufficiency, eug-
lycemic correction fails to restore glucose homeostasis or
improve growth rate and in fact worsens hypoxemia and
hypoinsulinemia, resulting in acidosis [50]. Therefore, the
metabolic changes associated with placental insufficiency
are dependent on placental oxygen supply and cannot be
alleviated by removing just the nutrient deprivation.
4. Skeletal Muscle Developmental Adaptations
to IUGR Conditions
The trajectory of skeletal muscle development and growth
is slowed in IUGR fetuses. Ultrasonic measurements of
IUGR fetuses show that muscle mass is reduced [51, 52],
and animal studies show that nutrient restriction impairs
fiber formation [53, 54]. Muscle fiber numbers, size, and
metabolic phenotypes develop at distinct fetal stages and
thus these aspects of muscle formation and growth are
affected differently depending upon the timing of the
fetal insult (Figure 1). Fiber numbers are determined by
myogenesis (formation of new fibers), which occurs in 3
distinct phases and is completed early in the third trimester
[55, 56]. Primary myotubes are generated from the fusion of
progenitor cells midway through the first trimester, creating
the scaffold around which smaller, secondary myotubes form
near the end of the first trimester. A final wave of secondary
(sometimes called tertiary) myotubes fills in the spaces not
already occupied by existing fibers and completes myogenesis
early in the third trimester. Nutritional insults during early or
mid-gestation interfere with myotube formation and reduce
fiber density in skeletal muscle. For example, maternal
nutrient restriction between the mid-first and mid-second
trimester in sheep lowers the number of secondary fibers
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Figure 1: The stages of skeletal muscle formation relative to gestational age are depicted by the horizontal arrows and schematic diagrams
(fascicular cross-sections) for the developmental process. The vertical dashed line represents the completion of myogenesis (new fiber
formation) and onset of hypertrophic fiber growth. The timing, duration, and type of nutritional insult (red boxes) reported in various
studies are presented below the gestational timeline, along with the fetal consequences (blue boxes).
per fasciculi in the fetal longissimus dorsi muscle [57]. In
pregnant ewes recovering from malnourishment at peri-
conception, secondary fiber density was also lower in the
fetal semitendinosus muscle [58]. Although IUGR can result
from maternal nutrient restriction during early gestation,
placental insufficiency does not cause fetal hypoxemia and
hypoglycemia until later stages of gestation, most likely
after myogenesis is complete [53, 54]. As a result, placental
insufficiency would reduce muscle mass by impairing fiber
growth to a greater extent than total fiber number.
After myogenesis, muscle growth continues via fiber
hypertrophy and requires myoblast incorporation to increase
genomic DNA content [59–65]. Myonuclei incorporation
precedes protein accumulation, and the size of a muscle fiber
is dependent on DNA content [59–63]. Because muscle fiber
myonuclei are postmitotic, DNA accumulation depends on
incorporation of new nuclei from myoblasts [66]. In fact,
50–99% of total skeletal muscle DNA content accumulates
postnatally [60]. In fetal sheep with placental insufficiency,
skeletal muscle fibers contain fewer myonuclei than fibers
from control fetuses, resulting in 33% less DNA, 40% less
RNA, and 76% less protein per fiber [53, 54]. Human
fetuses diagnosed as IUGR also have reduced skeletal muscle
DNA content in late gestation but have normal protein-
to-DNA ratios [67]. Our preliminary evidence indicates
that myogenic cell populations are smaller in IUGR fetal
skeletal muscle and that myoblasts isolated from IUGR fetal
sheep may proliferate and differentiate at slower rates than
those isolated from control fetuses (Yates, Limesand, and
Rhoads, unpublished). This scenario would indicate that
lower myonuclei content is a major limiting factor in IUGR
skeletal muscle fiber growth and that IUGR myoblasts are
impaired.
Histological measurements reveal a smaller proportion
of oxidative-to-glycolytic muscle fibers in some skeletal
muscles, which is another mechanism by which fetal devel-
opmental adaptations reduce muscle oxidative metabolism.
In the ovine tibialis cranialis, newly forming secondary fibers
express myosin-heavy chains for type II (glycolytic) fibers
exclusively, but under normal conditions, ∼60% of these
fibers stain positive for type I (oxidative) myosin-heavy
chains by the start of the third trimester [56]. The fiber-
type ratio continues to shift toward oxidative fibers until a
few weeks after birth [54, 68]. Together, these data reveal a
multifaceted defect in IUGR skeletal muscle growth, which
manifests in myoblast developmental programming that
lowers myonuclei content and alters fiber phenotypes, thus
preventing normal metabolic regulation.
5. Adrenergic Intervention: Catecholamines
Change the Regulatory Signals
Adaptations in skeletal muscle growth and metabolism
appear to be facilitated by chronic exposure to circulating
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Figure 2: Impact of placental insufficiency on endocrine responsiveness in fetal myoblasts andmyofibers. Adrenergic activity increases due to
greater circulating catecholamines. Adrenergic receptor β subtype-specific desensitization results in a greater proportion of signaling through
Adrβ1 and Adrβ3 because Adrβ2 expression is reduced. Insulin signaling is reduced due to adrenergic suppression of insulin secretion
in pancreatic β-cells and by muscle adrenergic signaling that negatively influences the insulin-Akt2 intercellular signaling pathway. These
developmental adaptations reduce rates of myoblast proliferation and differentiation as well as glucose metabolism in skeletal muscle.
catecholamines (Figure 2). In fact, intravenous infusion of
norepinephrine or epinephrine for 8 days reduces plasma
insulin and blood CO2, increases plasma lactate, and slows
hindlimb muscle growth rate in otherwise uncompromised
fetal sheep [69]. Catecholamines affect skeletal muscle
directly by selectively impairing insulin signaling and indi-
rectly by suppressing insulin secretion from pancreatic β cells
[70, 71]. Under normal conditions, insulin regulates muscle
metabolism by stimulating glucose uptake, glycogenesis,
glucose oxidation, and protein synthesis via the Akt2 and
MAPK-Erk1,2 signaling pathways [72–74] and by stimulat-
ing lipid metabolism via Akt1 [73]. Insulin also promotes
myoblast proliferation and differentiation [75–77] by activat-
ing Akt2 via IRS1 [73, 77–79], and increases protein synthesis
in fetal skeletal muscle [80, 81] and in myotubes derived
from isolated fetal myoblasts [82]. However, placental insuf-
ficiency in fetal sheep reduces plasma insulin by 78% [20, 26,
69, 83] and skeletal muscle Akt2 content by 40% [48]. Fur-
thermore, in adult rats chronically infused with epinephrine,
insulin administration is less effective in stimulating IRS1
tyrosine phosphorylation, IRS1 complex with PI3K and
SHP2, and Akt phosphorylation in skeletal muscle [84].
In adult humans, infusion of dobutamine (Adrβ1 agonist)
acutely reduces glucose oxidation rates and increases lipid
oxidation rates in skeletal muscle [85]. Salbutamol (Adrβ2
agonist) has no effect on glucose oxidation rates but slightly
increases lipid oxidation [85]. Furthermore, catecholamines
activate hormone-sensitive lipase to release fatty acids from
fat stores [86, 87], which may help replace glucose as a
metabolic substrate in muscle (Akt1 expression is not altered
by catecholamines [48]).
One major developmental adaptation in response to
chronic catecholamine exposure is modified adrenergic sig-
naling via alteration of Adrβ expression. Findings in other
tissues show that Adrβ1, Adrβ2, and Adrβ3 have subtype-
specific effects on insulin signaling. In adipocytes, Adrβ1 and
Adrβ3 stimulation reduces insulin signaling by uncoupling
IRS1 phosphorylation [88, 89] and Adrβ1 suppresses insulin
activation of Akt in cardiac muscle [90]. Conversely, Adrβ2
amplifies insulin activation of MAPK-Erk1,2 in ovarian cells
[91] and has been shown to stimulate myoblast proliferation
directly in chicks and mice [92, 93]. However, we have found
that expression of Adrβ2 is reduced in myoblasts isolated
from IUGR sheep fetuses (Table 1; Limesand and Yates, un-
published findings), meaning that adrenergic enhancement
of insulin signaling is reduced. Meanwhile, myoblast Adrβ1
and Adrβ3, which inhibit insulin-stimulated proliferation
and differentiation, are expressed normally. Likewise, Adrβ2
mRNA expression is reduced in hindlimb skeletal muscle
of IUGR fetal sheep and in those administered 7-day nore-
pinephrine infusions, but Adrβ1 and Adrβ3 expression
remain normal (SW Limesand and X Chen, unpublished
data). The end result is a greater inhibitory effect on skele-
tal muscle insulin signaling which, along with reduced
insulin secretion, would impair myoblast proliferation and
incorporation into muscle fibers and insulin-driven glucose
metabolism. Furthermore, skeletal muscle Adrβ2 continues
to be reduced in placental insufficiency-compromised lambs
at one month of age, showing that the adaptive Adrβ
profile may be a contributing factor in postnatal metabolic
disorders.
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Table 1: Adrenergic receptor β (Adrβ) mRNA expression determined by quantitative PCR in placental insufficiency-induced IUGR1 and
norepinephrine-infused2 sheep fetuses relative to control fetuses.
Treatment Age at necropsy Tissue
Adrβ
Adrβ1 Adrβ2 Adrβ3
PI-IUGR
Fetus, 134 dGA Myoblasts3 ↑28% ↓25% ↑800%
Fetus, 134 dGA Skeletal muscle4 NC ↓64% NC
Neonate, 28 days Skeletal muscle4 — ↓44% —
NE-Infused Fetus, 140 dGA Skeletal muscle4 NC ↓47% NC
1
Hyperthermia from 40 to 95 days of gestation (term ∼145 days).
2Intravenous norepinephrine (NE) infusions from 130 to 137 days of gestational age.
3Isolated from hindlimb skeletal muscles. n = 3/treatment.
4Pooled semitendinosus and biceps femoris. n = 6/treatment.
NC: no change; ↑: increased relative to controls; ↓: decreased relative to controls. Constitutive control was s15 for all samples.
6. Fetal Adaptations Persist in Postnatal Life
Hypoglycemia and hypoxemia are alleviated by birth, but
the thrifty metabolic adaptations persist into postnatal life
[4, 5]. Children born with SGA have less skeletal muscle
mass as infants and skeletal muscle mass grows at a slower
rate through four years of age compared to their AGA
counterparts [94–96]. Arm muscle size is reduced in infants
at birth and at 3, 6, and 9 months of age [97] and upper-arm
circumference and muscle area is less at 8 years of age [98].
Similarly, IUGR lambs have substantially reduced weight
and protein content in the semitendinosus muscles at birth
[53, 99], and daily protein accretion over the first fewmonths
of life is slowed [53]. As adults, SGA-born individuals have
less lean muscle, greater fat-to-muscle ratios [100–103], and
reduced muscle strength [102, 104]. Abdominal and leg
muscle mass is reduced in otherwise healthy men at 19
and 22 years of age [105], and total lean muscle is lower
at 50, 68, and 70 years of age [103, 106, 107]. In lambs
and piglets, IUGR also impairs perinatal development of the
vascular architecture [68, 108]. This may reflect an inability
of myocytes to stimulate angiogenesis [109, 110] and is likely
the origin of altered perfusion characteristics associated with
metabolic syndrome, including vascular resistance, reduced
responsiveness to adrenergic regulation, and endothelial
dysfunction [111]. After birth, myoblasts form solely from
the populations of quiescent satellite cells that develop
along the basal lamina of muscle fibers [54, 112]. These
populations, which control lifetime muscle growth and
repair, accrue during fetal development and are subjected
to IUGR conditions. Thus, the impairment of myoblast
proliferation and differentiation responsible for slowing fetal
skeletal muscle growth would also explain slower muscle
growth rates in children and reduced lean mass in adults.
The thrifty metabolic phenotype that develops in utero
also persists after birth. At 12 years of age, SGA-born children
exhibit similar basal metabolic rates compared to AGA-born
counterparts, but a smaller fraction of energy production is
due to glucose oxidation and a larger fraction is from lipid
oxidation [113]. Persistence of limited glucose oxidation
rates in IUGR skeletal muscle can be associated with a
combination of factors. First, less total lean muscle mass
requires less energy. This scenario explains lower rates of
systemic glucose oxidation but does not explain reduced
muscle-specific glucose uptake [113, 114]. Dulloo [115,
116] postulates a second factor for reduced skeletal muscle
glucose oxidation: glucose is preferentially redistributed
to adipose tissues to replenish depleted fat stores. This
“glucose redistribution hypothesis” has been applied to
the perinatal period after IUGR as well as recovery from
prolonged nutrient restriction at older ages [117]. However,
SGA-born individuals continue to exhibit thrifty glucose
metabolism throughout their lives, well after fat reserves are
replenished, which indicates that the timing of the insult
is important for persistence of the metabolic phenotype.
Evidence for the permanence of developmental adaptations
includes decreased oxidative-to-glycolytic fiber proportions
in 8-month-old sheep exposed to fetal nutrient restriction
and in mature pigs classified as runts (much smaller than
littermates) at birth [45, 118]. Skeletal muscle biopsies from
young-adult men born SGA reveal reduced insulin-signaling
enzymes (e.g., PI3K, p85α, p110β, PKCζ , Glut4) despite
normal insulin receptor content [119]. In rats, insulin sig-
naling via Akt is reduced in offspring from dams exposed to
a hypoxic or malnourished environment during pregnancy
[120]. Together, these studies indicate that the sustained
response is not completed after adipose stores are replenish
but is rather a product of a new nutrient utilization set-
point established by fetal developmental programming to
IUGR conditions. This phenomenon was described by Hales
and Barker [4, 5] as “metabolic dysregulation,” but the
connotation of a disorder may only apply because these
individuals are subjected to a lifetime of diets that exceed
their nutritional requirements.
7. Summary
Placental insufficiency results in conditions that restrict fetal
skeletal muscle development and growth by reducing the
capacity of the myofiber to maintain glucose homeostasis.
Altered adrenergic receptor expression profiles in myoblasts
and skeletal muscle of IUGR sheep fetuses indicate that
slower growth rates and thrifty metabolism are the result
of fetal adaptations to chronic catecholamine exposure in
utero. As the proportion of Adrβ2 to Adrβ1 declines in IUGR
skeletal muscle, adrenergic regulation promotes insulin
6 Journal of Pregnancy
resistance, reduced myoblast incorporation, less fiber hyper-
trophy, and lower rates of glucose oxidation. Developmental
programming of skeletal muscle adrenergic receptors in
utero helps explain metabolic and endocrine differences in
IUGR offspring as well, and the impact on metabolism may
result in differential nutrient utilization and requirements.
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